StockNews.com Begins Coverage on Avinger (NASDAQ:AVGR)

StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Avinger in a research report on Thursday, March 21st.

Avinger Stock Performance

Shares of AVGR opened at $3.69 on Wednesday. Avinger has a 52-week low of $2.50 and a 52-week high of $18.00. The business’s fifty day moving average is $3.41 and its 200-day moving average is $3.34. The firm has a market cap of $5.87 million, a price-to-earnings ratio of -0.14 and a beta of 1.26.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.52 million. As a group, research analysts forecast that Avinger will post -2.08 EPS for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.